Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new study builds on a successful collaboration and will compare T cell and antibody responses to uncover the role of ‘background’ immunity to virus strains already in circulation, including infections with similar coronaviruses.

The study is led by Professor Graham Ogg, who currently heads the MRC Human Immunology Unit at the MRC Weatherall Institute of Molecular Medicine, and Professor Neelika Malavige at the University of Sri Jayewardenepura. Professor Malavige is also a visiting researcher at Oxford University.

“We have worked together for 12 years to understand the response to dengue infections, and we now want to bring the expertise and knowledge we’ve acquired to understand the immune responses in individuals with COVID-19,” said Professor Ogg.

Current research indicates that immune responses to the novel SARS-CoV2 may be a key that distinguishes only a mild illness after infection from a more serious condition, but the workings of these immune responses are still poorly understood.

By comparing immune markers in blood samples from the UK versus Sri Lanka, the researchers hope to understand how existing immunity to different viruses (including other coronaviruses) might influence the immune response to a COVID-19 infection.

Read more on the Radcliffe Department of Medicine website

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.